Cannabinoids in multiple sclerosis (CAMS) study: Safety and efficacy data for 12 months follow up

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 76, Issue 12, 2005, Pages 1664-1669

  Zajicek, J P ^a   Sanders, H P ^b   Wright, D E ^b   Vickery, P J ^a   Ingram, W M ^a   Reilly, S M ^a   Nunn, A J ^a   Teare, L J ^a   Fox, P J ^a   Thompson, A J ^c  

^a PENINSULA MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF PLYMOUTH   (United Kingdom)

^c NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABINOID; CANNABIS; DRONABINOL; PLACEBO;

ABSCESS; ADULT; ANXIETY; ARTICLE; BARTHEL INDEX; BLADDER DISEASE; CELLULITIS; CHOLESTASIS; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DECUBITUS; DEPRESSION; DISEASE EXACERBATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ENTEROPATHY; FALLING; FATIGUE; FOLLOW UP; GASTROENTERITIS; GASTROINTESTINAL SYMPTOM; GENERAL HEALTH QUESTIONNAIRE; HEMATURIA; HUMAN; IMMOBILIZATION; INFECTION; INGUINAL REGION; LOCOMOTION; LONG TERM CARE; LUNG CARCINOMA; MAJOR CLINICAL STUDY; MEMORY DISORDER; MENTAL CONCENTRATION; MOTOR COORDINATION; MOTOR DYSFUNCTION; MULTIPLE SCLEROSIS; MUSCLE SPASM; MUSCLE STIFFNESS; MUSCLE WEAKNESS; NEUROLOGIC DISEASE; PAIN; PARESTHESIA; PATIENT MOBILITY; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RELAPSE; SCORING SYSTEM; SEIZURE; SIDE EFFECT; SKIN MANIFESTATION; SLEEP DISORDER; SPASTICITY; THORAX DISEASE; THORAX PAIN; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; TREMOR; URINARY TRACT INFECTION; UTERINE CERVIX CARCINOMA; VIRUS INFECTION; WALKING; XEROSTOMIA;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANALGESICS, NON-NARCOTIC; CANNABIS; DISABLED PERSONS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; PLACEBOS; PLANT EXTRACTS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 28144454955     PISSN: 00223050     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.2005.070136     Document Type: Article

References (10)

1. Consroe P, Musty R, Rein J, et al. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol 1977;38:44-8.
2. Skaper SD, Buriani A, Dal Toso R, et al. The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc Natl Acad Sci USA 1996;93:3984-9.
3. Hampson AJ, Grimaldi M, Axelrod J, et al. Cannabidiol and (-)delta9-tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci SA 1998;95:8268-73.
4. Panikashvili D, Simeonidou C, Ben-Shabat S, et al. An endogenous cannabinoid (2-AG) is neuroprotective after brain injury. Nature 2001;413:527-31.
5. Pryce G, Ahmed Z, Hankey DJ, et al. Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 2003;126:2191-202.
6. Zajicek J, Fox P, Sanders H, et al. Cannabinoids for treatment of spasticily and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet 2003;362:1517-26.
7. Gardner MJ, Altman DG. Statistics with confidence. London: British Medical Journal, 1989.
8. Wiles CM, Newcombe RG, Fuller KJ, et al. Controlled randomised crossover trial of the effects of physiotherapy on mobility in chronic multiple sclerosis. J Neurol Neurosurg Psychiatry 2001;70:174-9.
9. Riazi A, Fox P, Vickery J, et al. Developing a patient-based measure of the impact of spasticity in multiple sclerosis. Multiple Sclerosis 2003;9:S151.
10. Stocchi F, Olanow CW. Neuroprotection in Parkinson's disease: clinical trials. Ann Neural. 2003;53:S87-97; discussion S97-89, (suppl 3).